SCHEMBL3784547

SCHEMBL3784547

CC[C@@H](Nc1ncc[nH]1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
ASPH Q12797 1/20 0.46
KDM8 Q8N371 1/20 0.46
CDC7 O00311 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
DBF4 Q9UBU7 1/20 0.44
SCN1A P35498 1/20 0.41
SCN1B Q07699 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN8A Q9UQD0 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2C P18825 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
FDPS P14324 1/20 0.41
EGFR P00533 2/20 0.40
ATP1A1 P05023 1/20 0.40
ATP1B1 P05026 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1845819 1.00 KDM4E (0.46) KDM4EASPHKDM8CDC7CCNE1
SCHEMBL1845858 0.79 GAA (0.46) KDM4EASPHKDM8ADRA2AADRA2C
SCHEMBL3786576 0.79 GAA (0.46) KDM4EASPHKDM8ADRA2AADRA2C
SCHEMBL17985414 0.74 SCN1A (0.49) KDM4EASPHKDM8SCN1ASCN1B
SCHEMBL2507116 0.74 SCN1A (0.49) KDM4EASPHKDM8SCN1ASCN1B
SCHEMBL3258293 0.73 FPR2 (0.50) KDM4EADRA2AADRA2C
SCHEMBL11394003 0.71 LMNA (0.54) KDM4EASPHKDM8SCN1ASCN1B
SCHEMBL954734 0.70 CHRM2 (0.45) SCN1AADRA2AADRA2C
SCHEMBL2847032 0.69 LMNA (0.52) KDM4EASPHKDM8
SCHEMBL20852553 0.69 FDPS (0.44) ADRA2AADRA2CADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858653-B2 2-imidazoles HOFFMAN-LA ROCHE INC. (US) 2010-12-28 US claimed
US-20220280527-A1 TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT PURDUE PHARMA L.P. (US) 2022-09-08 US disclosed
US-20190201410-A1 TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT PURDUE PHARMA L.P. (US) 2019-07-04 US disclosed
EP-3463359-A1 TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT Purdue Pharma LP (US) 2019-04-10 EP disclosed
WO-2017210616-A1 TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT PURDUE PHARMA L.P. (US) 2017-12-07 WO disclosed
US-7858653-B2 2-imidazoles HOFFMAN-LA ROCHE INC. (US) 2010-12-28 US disclosed
US-20080146634-A1 2-IMIDAZOLES HOFFMANN-LA ROCHE INC. 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190201410-A1 TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT TAAR1, TAAR5, OPRL1 KDM4E 3900/4885ASPH 2194/4885KDM8 2986/4885
US-20220280527-A1 TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT TAAR1, TAAR5, OPRL1 KDM4E 3828/4885ASPH 2423/4885KDM8 2723/4885
US-20080146634-A1 2-IMIDAZOLES ABL1, H1-2, IPO4 KDM4E 915/4885ASPH 1562/4885KDM8 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.